Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy

J Infect Dis. 2003 Nov 15;188(10):1421-5. doi: 10.1086/379201. Epub 2003 Nov 5.

Abstract

We evaluated 1422 antiretroviral therapy (ART)-naive patients infected with human immunodeficiency virus (HIV) who initiated highly active antiretroviral therapy between 1 August 1 1996 and 31 July 2000 and were monitored until 31 March 2002. Patients were stratified on the basis of baseline levels of HIV RNA (<50,000, 50,000-99,999, and > or =100,000 copies/mL). Cox regression was used to determine independent predictors of time to death. After adjustment for adherence to ART and other potential confounders, baseline levels of HIV RNA of > or =100,000 copies/mL remained independently associated with mortality (adjusted relative hazard, 1.71; 95% confidence interval, 1.08-2.70; P=.023). If appropriately confirmed, these findings have important implications for the development of therapeutic guidelines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Disease Progression
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / mortality
  • HIV Infections / virology*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / genetics*
  • Humans
  • Male
  • Patient Compliance
  • Proportional Hazards Models
  • Prospective Studies
  • RNA, Viral / blood*
  • Reverse Transcriptase Inhibitors / therapeutic use*

Substances

  • HIV Protease Inhibitors
  • RNA, Viral
  • Reverse Transcriptase Inhibitors